Richard John Maunder, MD | |
2500 Ne Neff Rd, Bend, OR 97701-6015 | |
(541) 706-5880 | |
(541) 706-6372 |
Full Name | Richard John Maunder |
---|---|
Gender | Male |
Speciality | Internal Medicine - Hospice And Palliative Medicine |
Location | 2500 Ne Neff Rd, Bend, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295727535 | NPI | - | NPPES |
072561 | Medicaid | OR | |
8574709 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | MD19375 (Oregon) | Secondary |
207RH0002X | Internal Medicine - Hospice And Palliative Medicine | MD 19375 (Oregon) | Primary |
Mailing Address | Practice Location Address |
---|---|
Richard John Maunder, MD 2500 Ne Neff Rd, Bend, OR 97701-6015 Ph: (541) 706-5880 | Richard John Maunder, MD 2500 Ne Neff Rd, Bend, OR 97701-6015 Ph: (541) 706-5880 |
News Archive
CDEX Inc. announces completion of development-phase testing of a new generation Meth Scannerâ„¢ that embodies cell-phone technology and multi-filter applications. The new generation Scanner will have a cell-phone-interactive readout that increases functionality to provide more options for the law enforcement community in its battle against methamphetamine use. In addition, the technological advancements of multi-filter integration will provide greater sensitivity and a platform for multi-drug applications for the Scanner.
Peptides that target blood vessels in fat and cause them to go into programmed cell death (termed apoptosis) could become a model for future weight-loss therapies, say University of Cincinnati (UC) researchers.
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.
Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 2 days ago
Alanna Mozena, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Ashley Marie Twyman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Dr. Gilbert B. Lee, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1558 Sw Nancy Way, Bend, OR 97702 Phone: 541-312-8679 | |
Ms. Christine Marie Pierson, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2965 Ne Conners Ave, Ste 280, Bend, OR 97701 Phone: 541-323-4269 | |
Dr. Michael N Harris, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-2811 | |
Gordon Jeremy Juriansz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 | |
Dr. Ronald Daniel Rosen, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 918 Ne 5th St, Bend, OR 97701 Phone: 541-388-3804 Fax: 541-388-3856 |